Compare Fabrinet (FN) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Koninklijke Philips NV — how do they compare? Fabrinet trades at $487.52 (market cap $17.46B), while Koninklijke Philips NV trades at $24.25 (market cap $23.52B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays a 4.17% dividend while Fabrinet pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Koninklijke Philips NV for 84 Days on average.
| FN | PHG | |
|---|---|---|
Market Cap | $17.46B | $23.52B |
Volume | 1,199,886 | 1,635,069 |
Sector | Technology | Health |
52-Week High | $746.47 | $32.91 |
52-Week Low | $361.94 | $23.81 |
Typical Hold Time | 30 Days | 84 Days |
Enterprise Value | $16.59B | $29.87B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $486.8, down 2.25% on the day, amid a mixed technical picture with a bullish moving average signal but overbought RSI levels. Fundamentally, the company shows strong growth with Q2 2026 EPS of $4.10 beating expectations, revenue projected to rise to $4.6B in 2026, and robust profitability metrics including a 21.33% ROE. Recent news highlights surging AI data center demand driving expansion.
The outlook is positive given analyst consensus of a $769.50 price target and 75% buy ratings, though risks include customer concentration and high capital expenditures impacting cash flow. The stock offers exposure to AI infrastructure growth but requires monitoring of execution and competitive pressures.
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
